--- title: "Allogene Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286309448.md" datetime: "2026-05-13T20:07:09.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286309448.md) - [en](https://longbridge.com/en/news/286309448.md) - [zh-HK](https://longbridge.com/zh-HK/news/286309448.md) --- # Allogene Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.18, beating the estimate of USD -0.19. #### License Agreement Financial Terms Allogene Therapeutics, Inc. received an upfront payment of $40.0 million under the now-terminated Exclusive License Agreement with Overland Therapeutics (SH) Co. Ltd. and Overland Therapeutics Inc. The company also received non-cash consideration of $79.0 million in the form of shares of series seed preferred stock of Overland under the terminated agreement. Allogene Therapeutics, Inc. was entitled to additional regulatory milestone payments of up to $40.0 million, if achieved, under the License Agreement. A flat mid single-digit royalty on net sales in the licensed territory was also part of the agreement. No termination payments were made in connection with the Termination Agreement. Following the surrender of a portion of its equity interests in Overland for no consideration, Allogene Therapeutics, Inc. expects to hold approximately 3% of Overland’s outstanding equity on an as-converted and fully diluted basis. #### Quarterly Financial Results Specific operational metrics such as net income, gross margin, operating profit, operating costs, and cash flow for the quarter ended March 31, 2026, are not detailed within this reference. #### Financial Performance for Q1 2026 Research and Development Expenses were $32.0 million for the first quarter of 2026, a decrease from $50.2 million in the first quarter of 2025. This included $2.7 million of non-cash stock-based compensation expense for Q1 2026. General and Administrative Expenses were $14.1 million for the first quarter of 2026, a decrease from $14.991 million in the first quarter of 2025. This included $5.6 million of non-cash stock-based compensation expense for Q1 2026. Total Operating Expenses were $46.092 million for the first quarter of 2026, down from $65.191 million in the first quarter of 2025. Loss from Operations was - $46.092 million for the first quarter of 2026, compared to - $65.191 million for the first quarter of 2025. Interest and Other Income, Net, was $3.573 million for the first quarter of 2026, decreasing from $5.516 million in the first quarter of 2025. Interest Expense was - $0.3 million for the first quarter of 2026, an increase from - $0.15 million in the first quarter of 2025. Other Income (Expenses), Net, was $0.212 million for the first quarter of 2026, compared to $0.092 million in the first quarter of 2025. Total Other Income (Expenses), Net, was $3.485 million for the first quarter of 2026, down from $5.458 million in the first quarter of 2025. Net Loss was - $42.607 million for the first quarter of 2026, an improvement from - $59.733 million in the first quarter of 2025. This included $8.3 million of non-cash stock-based compensation expense for Q1 2026. Net Loss Per Share, Basic and Diluted, was - $0.18 for the first quarter of 2026, compared to - $0.28 for the first quarter of 2025. #### Balance Sheet Highlights Allogene Therapeutics, Inc. ended the first quarter of 2026 with $266.9 million in Cash, Cash Equivalents and Investments, an increase from $258.253 million as of December 31, 2025. Total Assets were $395.958 million as of March 31, 2026, a decrease from $415.905 million as of December 31, 2025. Total Liabilities were $117.083 million as of March 31, 2026, a decrease from $123.363 million as of December 31, 2025. Total Stockholders’ Equity was $278.875 million as of March 31, 2026, a decrease from $292.542 million as of December 31, 2025. #### Capital Activities A public offering in April 2026 generated aggregate gross proceeds of $200.4 million. #### Operational Metrics and Clinical Trial Updates In the Cema-cel (ALPHA3 Trial), an interim futility analysis showed 58.3% (7⁄12) of patients in the cema-cel arm achieved Minimal Residual Disease (MRD) clearance, compared to 16.7% (2⁄12) in the observation arm. At Day 45, ctDNA levels decreased by a median of 97.7% from baseline in the cema-cel arm versus a median increase of 26.6% in the observation arm. The therapy demonstrated a favorable safety profile with no CRS, ICANS, GvHD, or treatment-related serious adverse events or hospitalizations. Approximately one-third of screening activity and cema-cel infusions occurred at community cancer centers. For the ALLO-329 (RESOLUTION Trial), nine patients have been treated across Dose Level 1 (20 Million Cells) and Dose Level 2 (40 Million Cells) since enrollment began in November 2025. Initial observations at early dose levels show signs of clinical activity and favorable tolerability. #### Outlook and Guidance Allogene Therapeutics, Inc. has extended its cash runway into the first quarter of 2029 due to the recent public offering. The company is modestly increasing its guidance for operating cash expense in 2026 from approximately $150 million to $165 million, and GAAP Operating Expenses are also expected to modestly increase from approximately $210 million to $225 million, including estimated non-cash stock-based compensation expense of approximately $35 million. Allogene Therapeutics, Inc. anticipates an interim Event-Free Survival (EFS) analysis for the ALPHA3 trial in mid-2027 and the primary EFS analysis in mid-2028, with the next update for the RESOLUTION trial expected in Q4 2026. ### Related Stocks - [ALLO.US](https://longbridge.com/en/quote/ALLO.US.md) ## Related News & Research - [Allogene Therapeutics ends China cell therapy deal with Overland](https://longbridge.com/en/news/286317303.md) - [Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)](https://longbridge.com/en/news/286408124.md) - [Allogene Therapeutics - Enters Termination Agreement With Overland Therapeutics On May 12, 2026 - SEC Filing](https://longbridge.com/en/news/286315271.md) - [Key facts: Allogene ends Overland license; ALPHA3 58.3% MRD‑negativity](https://longbridge.com/en/news/286380061.md) - [Luke Evnin Sells 22,184 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock](https://longbridge.com/en/news/287219594.md)